Provided by Tiger Fintech (Singapore) Pte. Ltd.

Repare Therapeutics Inc.

1.20
+0.0000
Post-market: 1.200.00000.00%18:09 EDT
Volume:418.21K
Turnover:518.13K
Market Cap:51.01M
PE:-0.60
High:1.30
Open:1.20
Low:1.20
Close:1.20
Loading ...
May 07, 2024

Major Issues Report

Form 8-K - Current report
Apr 26, 2024

Major Issues Report

Form 8-K - Current report
Mar 28, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 27, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 26, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 26, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 26, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 28, 2024

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Feb 28, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 28, 2024

Major Issues Report

Form 8-K - Current report
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 12, 2024

Major Issues Report

Form 8-K - Current report
Jan 30, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Jan 25, 2024

Major Issues Report

Form 8-K - Current report
Jan 13, 2024

Major Issues Report

Form 8-K - Current report
Nov 18, 2023

Beneficial Ownership Change

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Nov 15, 2023

Major Issues Report

Form 8-K - Current report
Nov 09, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]